Thursday, Sep 24, 2020 | Last Update : 04:45 AM IST

183rd Day Of Lockdown

Maharashtra122438091634833015 Andhra Pradesh6317495518215410 Tamil Nadu5473374919718871 Karnataka5268764233778145 Uttar Pradesh3588932895945135 Delhi2492592133045014 West Bengal2283021989834421 Odisha184122149379763 Telangana1726081419301042 Bihar169856155824870 Assam159320129130578 Kerala13863398720554 Gujarat1247671051913337 Rajasthan116881972841352 Haryana113075908841177 Madhya Pradesh108167836182007 Punjab99930754092860 Chhatisgarh8618347653680 Jharkhand7267358543626 Jammu and Kashmir65026421151024 Uttarakhand4177729000501 Goa2875322726360 Puducherry2319118065467 Tripura2227215441245 Himachal Pradesh124387836125 Chandigarh102987411123 Manipur9010683859 Arunachal Pradesh7385540813 Nagaland5544445110 Meghalaya4733252838 Sikkim2447190529 Mizoram158510120
  Life   Health  22 Sep 2019  Brain cancer in kids can be treated with leukemia drug

Brain cancer in kids can be treated with leukemia drug

Published : Sep 22, 2019, 12:21 pm IST
Updated : Sep 22, 2019, 12:21 pm IST

Leukemia drug may treat brain cancer in children: Study.

New use of leukemia drug, nilotinib to heal a deadly pediatric brain cancer. (Photo: ANI)
 New use of leukemia drug, nilotinib to heal a deadly pediatric brain cancer. (Photo: ANI)

Washington: In a recent study, researchers suggested a new use of leukemia drug, nilotinib to heal a deadly pediatric brain cancer called medulloblastoma.

In the study, published in September in -- PLOS One -- the team demonstrated how use of a single drug, in this case nilotinib, specifically targets cancer cells that have an abnormal activation of a cell communication system, called the Hedgehog pathway, via two different mechanisms, making it more effective and less toxic than combining drugs.


"We discovered a previously unknown activity of nilotinib that may be leveraged to treat a large fraction of cases of medulloblastoma, a type of childhood brain cancer," said senior author Ruben Abagyan, PhD, a professor in the Skaggs School of Pharmacy.

"While more research is needed, this pharmaceutical could potentially be used for several cancer types with an overactive cell-signaling pathway," added Abagyan.

Several types of basal cell carcinoma, myeloid leukemia, rhabdomyosarcoma, pancreatic adenocarcinoma, glioblastoma and one-third of medulloblastoma cases have impairment in the Hedgehog signaling pathway, a key cellular system that regulates embryonic development and adult tissue regeneration.


As a result of this impairment, the cancer cells overproduce a cell-surface receptor called Smoothened. Malignancies with this abnormality account for a quarter of all cancer deaths said Abagyan.

"Only a fraction of patients with this subtype of medulloblastoma respond well to current therapies that only target Smoothened," said Abagyan.

"Knowing that dysregulation of the Hedgehog pathway is important to the maintenance of cancer stem cells and that it plays a critical role in several cancers, we wanted to find a single drug that inhibits this pathway in addition to several other essential anti-cancer activities," added Abagyan.

In the study, Abagyan and team discovered that mice bearing human medulloblastoma tumours saw tumour growth reduced and no drug resistance occurring. Nilotinib simultaneously inhibits Smoothened and several protein kinases critical for tumor growth.


Tags: leukemia, brain cancer, cancer treatment, tumors